order
present
knowledg
emerg
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
differ
specimen
patient
clinic
diagnosi
sar
investig
presenc
viral
rna
plasma
specimen
patient
examin
igm
igg
antibodi
specif
sarscov
use
indirect
elisa
viral
rna
detect
patient
test
cumul
data
show
sar
patient
demonstr
seroconvers
week
ill
contrast
healthi
subject
enrol
studi
found
posit
igg
antibodi
coexist
viral
rna
plasma
specif
antibodi
simultan
observ
three
consecut
week
two
critic
case
three
convalesc
patient
particular
cultiv
sarscov
detect
stool
urin
specimen
longer
week
day
find
suggest
sarscov
may
remain
viabl
excret
convalesc
patient
sever
acut
respiratori
syndrom
sar
newli
emerg
human
infecti
diseas
result
global
death
probabl
case
date
novel
coronaviru
identifi
etiolog
sarscov
contain
singlestrand
plussens
rna
genom
approxim
kb
length
typic
five
major
open
read
frame
orf
encod
replicas
r
polyprotein
spike
envelop
e
membran
nucleocapsid
n
protein
sarscov
infect
african
green
monkey
kidney
vero
cell
vitro
experiment
caus
similar
diseas
cynomolgu
macaqu
macaca
fasciculari
report
around
patient
probabl
sar
gener
antibodi
sarscov
figur
neglig
healthi
popul
earli
laboratori
diagnost
assay
base
convent
nest
andor
realtim
revers
transcriptionpolymeras
chain
reaction
rtpcr
develop
detect
viral
rna
clinic
specimen
sar
patient
even
though
viral
rna
antibodi
profil
sar
patient
well
studi
simultan
detect
profil
sera
plasma
rare
document
particular
pauciti
data
concern
viral
vital
excret
sar
patient
convalesc
phase
studi
present
viral
rna
detect
differ
type
clinic
specimen
dynam
profil
sarscov
rna
plasma
antibodi
sarscov
simultan
investig
patient
probabl
sar
viral
rnaposit
stool
urin
sampl
patient
studi
viral
vital
result
obtain
avail
knowledg
regard
laboratori
diagnost
prophylact
control
emerg
infect
total
clinic
specimen
patient
clinic
diagnosi
sar
test
presenc
viral
rna
specif
antibodi
sarscov
specimen
includ
plasma
sampl
isol
citrat
sodiumanticoagul
peripher
blood
blood
cell
sampl
remain
part
blood
plasma
sputumthroat
swab
sampl
stool
specimen
urin
specimen
possibl
specimen
collect
weekli
moreov
plasma
specimen
addit
patient
test
sole
presenc
sarscov
antibodi
patient
hospit
unit
march
june
clinic
diagnosi
sar
receiv
ribavirinsteroid
combin
therapi
addit
plasma
sampl
healthi
subject
analyz
presenc
antibodi
specif
sarscov
specimen
store
c
test
rna
extract
perform
biosafeti
level
laboratori
beij
hospit
rna
extract
directli
plasma
urin
sampl
sputum
sampl
shaken
min
equal
volum
acetylcystein
sodium
chlorid
supernat
isol
centrifug
g
min
throat
swab
stool
sampl
suspend
phosphatebuff
salin
pb
contain
uml
rnasin
promega
madison
wi
usa
shaken
min
supernat
isol
centrifug
mention
blood
cell
ml
blood
treat
equal
volum
trizol
invitrogen
carlsbad
ca
usa
follow
isol
aqueou
phase
centrifug
g
min
rna
extract
use
qiamp
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
nest
rtpcr
two
group
nest
primer
use
amplifi
viral
rna
one
set
bni
primer
recommend
word
health
organ
use
target
r
polyprotein
encod
region
sarscov
outer
senseantisens
primer
atgaa
cataaccagtcg
inner
senseantisens
primer
ctgtagaa
result
fragment
complementari
nucleotid
strain
viral
genom
genbank
access
anoth
set
primer
use
target
n
proteinencod
region
sarscov
design
use
sequenc
analysi
softwar
macvector
accelri
san
diego
ca
usa
outer
senseantisens
primer
inner
senseantisens
primer
tgcacaattt
tgcttgttcagcagtatgacg
result
fragment
complementari
nucleotid
strain
viral
genom
onestep
rtpcr
kit
qiagen
use
revers
transcript
first
round
pcr
amplif
outer
primer
thermal
cycl
consist
c
min
c
min
cycl
c
c
decreas
c
everi
cycl
c
cycl
c
c
c
afterward
product
use
templat
second
round
pcr
amplif
volum
inner
primer
taq
dna
polymeras
mbi
fermenta
hanov
md
usa
thermal
cycl
consist
cycl
c
c
c
reaction
care
carri
avoid
contamin
posit
neg
control
includ
reaction
run
rtpcr
product
analyz
electrophoresi
agaros
gel
contain
ethidium
bromid
confirm
result
dna
electrophoret
band
right
size
recov
use
qiaquick
gel
extract
kit
qiagen
clone
pgemt
vector
system
promega
sequenc
analysi
dna
sequenc
obtain
use
autom
sequenc
appli
biosystem
foster
citi
ca
usa
analysi
comparison
nucleotid
carri
dnastar
comput
softwar
dnastar
madison
wi
usa
plasma
igm
igg
antibodi
specif
sarscov
detect
use
two
commerci
avail
elisa
kit
jibiai
biotech
beij
china
accord
manufactur
instruct
indirect
assay
employ
use
elisa
kit
cultureobtain
sarscov
antigen
captur
antibodi
experi
carri
laboratori
beij
genom
institut
chines
academi
scienc
stool
suspend
pb
supernat
isol
centrifug
steril
pass
millipor
filter
spread
onto
monolay
vero
cell
plate
urin
clarifi
centrifug
steril
spread
onto
cell
way
control
pb
use
instead
clinic
specimen
triplic
well
incub
c
h
infect
solut
replac
fresh
dulbecco
minimum
essenti
medium
fetal
calf
serum
gibco
brl
grand
island
ny
usa
cultur
examin
cytopath
effect
cpe
day
day
blind
passag
perform
cell
collect
vigor
blow
monolay
cell
medium
cell
suspens
treat
three
round
freezethaw
condit
clarifi
centrifug
spread
onto
fresh
vero
cell
blind
passag
perform
week
week
discard
cpe
observ
cpe
appear
cell
collect
electron
microscopi
observ
rtpcr
identif
isol
sarscov
confirm
sequenc
analysi
rtpcr
product
one
hundr
nine
specimen
sar
patient
posit
sarscov
rna
nest
rtpcr
result
detect
rate
amplifi
fragment
bp
length
confirm
part
sarscov
polymeras
gene
n
gene
respect
sequenc
analysi
fig
posit
sampl
doubl
posit
r
n
gene
fragment
amplif
individu
singleposit
amplif
r
n
gene
fragment
observ
sampl
respect
viral
rna
detect
patient
test
week
week
ill
respect
detect
profil
viral
rna
differ
specimen
shown
fig
specimen
obtain
respiratori
tract
like
specimen
yield
viral
rna
earli
stage
ill
seven
eight
test
patient
test
specimen
posit
week
convalesc
phase
infect
ie
week
diseas
onset
viral
rna
detect
differ
specimen
patient
figur
show
dynam
seroconvers
cumul
percentag
patient
probabl
sar
difficulti
associ
clinic
sampl
collect
plasma
sampl
could
collect
sar
patient
three
consecut
week
test
sarscov
rna
antibodi
among
patient
detect
antibodi
one
specimen
posit
viral
rna
tabl
two
patient
persist
posit
viral
rna
plasma
week
diseas
onset
notabl
coexist
specif
antibodi
viral
rna
observ
long
week
two
patient
twentyon
stool
urin
specimen
employ
vitro
isol
sarscov
sputum
specimen
employ
use
acetylcystein
viral
rna
extract
process
may
destroy
protein
structur
viru
plasma
blood
specimen
employ
low
viral
load
sampl
nest
rtpcr
show
stool
urin
specimen
posit
viral
rna
r
n
gene
fragment
either
r
n
gene
fragment
five
neg
viral
rna
sarscov
isol
ten
specimen
posit
r
n
gene
fragment
viral
rna
gener
passag
cultur
emerg
cpe
viru
vero
cell
fig
ident
confirm
rtpcr
follow
sequenc
analysi
contrast
viru
isol
specimen
tabl
area
affect
sar
epidem
world
date
beij
claim
case
death
earli
march
late
may
case
sar
patient
hospit
treat
unit
beij
hospit
includ
first
cluster
casepati
area
criteria
laboratori
confirm
sarscov
infect
base
follow
method
sarscov
rna
detect
rtpcr
serolog
detect
sarscovrel
antibodi
isol
sarscov
cell
cultur
tabl
sever
assay
develop
detect
viral
rna
use
convent
nest
rtpcr
realtim
rtpcr
though
realtim
rtpcr
assay
quantit
advantag
report
higher
sensitivityspecif
case
requir
expens
reagent
special
instrument
obstacl
prevent
widespread
use
ordinari
laboratori
crucial
time
span
sar
epidem
realtim
rtpcr
assay
still
develop
therefor
convent
nest
rtpcr
still
serv
practic
assay
time
method
use
bni
outerinn
primer
report
lower
cost
similar
sensit
specif
compar
three
inhous
realtim
rtpcr
assay
observ
simultan
employ
primer
target
r
orf
n
region
sarscov
could
increas
method
detect
sensit
find
ident
contain
previou
report
bressler
et
al
author
suggest
n
gene
present
subgenom
rna
sarscov
instead
one
orf
r
gene
howev
believ
major
reason
might
sarscov
intact
clinic
specimen
thu
amplif
differ
region
sarscov
increas
chanc
detect
disintegr
viru
genom
nest
rtpcr
may
give
occasion
falseposit
reaction
stool
specimen
test
stool
specimen
sputum
specimen
healthi
subject
use
assay
falseposit
reaction
observ
four
stool
specimen
therefor
posit
result
stool
specimen
sar
patient
confirm
sequenc
analysi
rtpcr
product
addit
posit
sampl
amplifi
sequenc
gene
sarscov
confirm
sampl
contain
gene
fragment
sarscov
employ
variou
specimen
may
increas
detect
rate
viral
rna
present
studi
viral
rna
detect
patient
probabl
sar
week
week
ill
respect
contrast
specif
antibodi
sarscov
detect
patient
respect
week
therefor
viral
rna
detect
particularli
valuabl
earlystag
diagnost
howev
falseposit
result
care
exclud
especi
stool
specimen
employ
nasopharyng
aspir
collect
profession
physician
use
qualifi
realtim
rtpcr
assay
may
increas
method
sensitivityspecif
week
follow
diseas
onset
serolog
gold
standard
identifi
trueposit
case
sinc
sarscov
new
human
commonli
lack
immun
studi
patient
clinic
diagnosi
sar
neg
seroconvers
two
children
patient
tabl
interest
howev
viral
rna
detect
patient
ie
blood
cell
sampl
patient
plasma
sampl
patient
investig
report
half
pediatr
patient
clinic
diagnosi
sar
fail
develop
detect
antibodi
specif
sarscov
weak
humor
immun
respons
pediatr
sar
patient
may
respons
unusu
phenomenon
sinc
observ
four
adult
patient
seroconvert
termin
week
ill
seroconvers
still
occur
week
ill
one
possibl
explan
neg
antibodi
detect
result
may
delay
antibodi
respons
also
possibl
antibodi
respons
patient
sensit
elisa
test
howev
consid
sar
diagnosi
patient
base
clinic
manifest
characterist
chest
radiograph
emerg
situat
clinic
misdiagnosi
patient
neg
sarscov
rna
exclud
healthi
subject
test
one
individu
posit
igg
antibodi
plasma
suggest
silent
infect
sarscov
unlik
gener
seroconvers
occur
parallel
erad
viru
plasma
serum
studi
howev
persist
coexist
sarscov
rna
antibodi
sarscov
observ
plasma
two
patient
whose
clinic
statu
critic
investig
also
report
longterm
persist
sarscov
rna
serum
sarscovspecif
igg
seroconvert
previous
document
presenc
sarscov
quasispeci
individu
patient
therefor
remain
clarifi
whether
persist
coexist
viral
rna
specif
antibodi
correl
dynam
genet
variat
viru
vitro
passag
vero
cell
sarscov
isol
seven
stool
three
urin
specimen
posit
n
r
region
viral
rna
use
nest
rtpcr
includ
two
stool
specimen
one
urin
specimen
collect
week
diseas
onset
knowledg
isol
viabl
sarscov
urin
convalesc
patient
report
previous
isol
live
sarscov
stool
specimen
convalesc
sar
patient
discrep
one
report
accord
find
anoth
investig
discrep
may
due
differ
isol
protocol
result
suggest
viabl
sarscov
might
exist
excret
convalescentphas
patient
sinc
yet
known
precis
long
sarscov
remain
activ
vivo
measur
taken
prevent
spread
infecti
agent
via
excret
convalesc
individu
result
retrospect
studi
depict
dynam
profil
viral
persist
seroconvers
sar
patient
reveal
novel
find
viabl
sarscov
shed
urin
stool
convalescentphas
patient
result
current
knowledg
emerg
infecti
diseas
offer
implic
clinic
diagnost
infect
control
